Vaccitech: Dr Anne Phillips, Karen A. Dawes, Dr Joseph Scheeren
Vaccitech, a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer, has appointed three new independent directors to its Board of Directors.
Dr. Anne Phillips, FRCPC, Karen A. Dawes, MBA and Joseph Scheeren, PharmD, have joined the board over the last two months.
Dr. Phillips has extensive biopharmaceutical product development experience. She currently serves as Senior Vice President Clinical, Medical & Regulatory Affairs at Novo Nordisk, where she has overseen more than a dozen FDA drug approvals.
Prior to this, she served in multiple executive roles in drug development at GlaxoSmithKline including Vice President Medicine Development Leader of a leading prostate cancer therapeutic. Before building a long career in the pharmaceutical industry, Dr. Phillips served as Head of Infectious Diseases programs and Deputy Physician-in-chief at Wellesley Central Hospital/St. Michael’s Hospital in Toronto, Canada.
Ms. Dawes has served as an executive at several biopharmaceutical companies including Bayer Corp., Wyeth Pharmaceuticals, Genetics Institute and Pfizer, where she held leadership roles in business, marketing and commercialization. More recently, Ms. Dawes has led her own successful consultancy company working with emerging companies on corporate strategy and commercial development.
Since 2005, Ms. Dawes has served on the boards of several public and private biopharmaceutical companies, and she continues to serve on the boards of Repligen Corp., Medicines 360, Medicenna Therapeutics and PaxMedica Therapeutics.
Dr. Scheeren's expertise is in research and development and regulatory affairs in the pharmaceutical industry. He recently retired from his role as President and Chief Executive Officer of Critical Path Institute, a non-profit organization that validates tools to accelerate drug development.
He has previously held various senior roles at Bayer AG for 15 years, including as head of global regulatory affairs. His career has also included executive positions at Aventis Pharmaceuticals, Roussel UCLAF, Ares Serono and Les Laboratoires Servier. He currently serves as a director on several boards of non-profit organizations, is an adjunct Professor of Regulatory Science at Peking University, Beijing, and is a lecturer at Yale University. Dr Scheeren earned his PharmD at the University of Leiden, Leiden, the Netherlands, School of Pharmacy.
